The state of New Mexico currently has 2 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Albuquerque, Santa Fe, Las Cruces and Farmington.
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Recruiting
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in u... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/12/2024
Locations: New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico
Conditions: Parkinson's Disease Psychosis
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias